SLC6A8 and neoplasm: SLC6A8 (CRT1) is related to cancer patients’ survival, immune checkpoint genes, and tumor-infiltrating immune cell abundances, and is relatively accurate in identifying possible cancer patients; it contains mutations, amplifications, and deletions that might be involved in tumorigenesis through carbon metabolism and the HIF-1 signaling pathway [39].